Relationship between pre-sarcopenia and quality of life in patients with chronic liver disease: a cross-sectional study

Ohashi, Kazuki; Ishikawa, Toru; Imai, Michitaka; Suzuki, Mizuto; Hoshii, Asami; Abe, Hiroko; Koyama, Fujiko; Nakano, Tomomi; Ueki, Aya; Noguchi, Hirohito; Hasegawa, Erina; Hirosawa, Shiori; Kobayashi, Miki; Hirosawa, Hiroshi; Sato, Kaede; Munakata, Miyu; Yoshida, Toshiaki

doi:10.1097/meg.0000000000001415

Cited by 18 publications

(10 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…28 Ohashi et al also reported that an independent predictive factor for presarcopenia was being female among patients with CLD. 29 A possible reason why women are more likely to have muscle atrophy than men is the physical activity of women, as women is known to engage in fewer physical activities than men. 30 In addition, testosterone is a powerful anabolic agent that promotes muscle protein synthesis and subsequently increases muscle mass.…”

Section: Discussionmentioning

confidence: 99%

Clinical utility of the Liver Frailty Index for predicting muscle atrophy in chronic liver disease patients with hepatocellular carcinoma

Hirota

Kawaguchi

Koya

et al. 2019

Hepatology Research

View full text Add to dashboard Cite

Aim Muscle atrophy is a prognostic factor for patients with chronic liver disease (CLD) and hepatocellular carcinoma (HCC). The Liver Frailty Index (LFI) is a simple physical function test; however, an association between LFI and muscle mass remains unclear. We aimed to investigate the utility of LFI for predicting muscle atrophy in CLD patients with HCC. Methods We enrolled 138 CLD patients with HCC (aged 77 years, female/male 34.8%/65.2%). Muscle mass was assessed by skeletal muscle index, and patients were classified into the muscle atrophy group (n = 109) or the non‐muscle atrophy group (n = 29). Physical frailty was assessed by LFI. The optimal cut‐off value of LFI for predicting muscle atrophy was identified by receiver operating characteristic analysis. Results In the muscle atrophy group, the prevalence of pre‐frail/frail was significantly higher than the non‐muscle atrophy group (87.2% vs. 58.6%, P = 0.0005). In the logistic regression analysis, being female and pre‐frail/frail were identified as independent factors associated with muscle atrophy (pre‐frail/frail; OR 3.601, 95% CI 1.381–9.400, P = 0.0088). In patients with normal grip strength, 71.1% of patients were pre‐frail/frail, in which 82.8% of patients showed muscle atrophy. Receiver operating characteristic statistics provided an area under the curve of 0.74, and an LFI cut‐off value of 2.94 for predicting muscle atrophy (sensitivity 88.06%, specificity 52.17%, accuracy 77.91%). Conclusions We showed that pre‐frail/frail was an independent factor for muscle atrophy in CLD patients with HCC. Furthermore, LFI predicted muscle atrophy with high sensitivity, even in patients with normal grip strength. Thus, LFI might be a useful screening tool for muscle atrophy in CLD patients with HCC.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical utility of the Liver Frailty Index for predicting muscle atrophy in chronic liver disease patients with hepatocellular carcinoma

Hirota

Kawaguchi

Koya

et al. 2019

Hepatology Research

View full text Add to dashboard Cite

show abstract

“…However, at present, there is little research on the effects of muscle strength on OS in patients with CLDs 19,21 . Loss of SMM has been reported to increase the risk of minimal hepatic encephalopathy, 23 reduced QOL, 24 and unfavorable prognosis in HCC 25,26 and liver transplantation, 27,28 amongst others.…”

Section: Introductionmentioning

confidence: 99%

Reduced handgrip strength predicts poorer survival in chronic liver diseases: A large multicenter study in Japan

Nishikawa

Shiraki

Hiramatsu

et al. 2021

Hepatology Research

View full text Add to dashboard Cite

Aim Sarcopenia has a high prevalence and can be an adverse predictor in patients with chronic liver diseases (CLDs). We sought to assess the prevalence of sarcopenia and its prognostic significance in patients with CLDs at multiple centers in Japan. Methods In this retrospective study, we collated the data of 1624 patients with CLDs (976 men). The diagnosis of sarcopenia was determined by the sarcopenia assessment criteria of the Japan Society of Hepatology. Predictors of mortality were identified using univariate and multivariate analyses. Results Muscle weakness and skeletal muscle loss occurred in 33.5% and 29.3% of all subjects, respectively, while sarcopenia occurred in 13.9% of all patients. Patients with sarcopenia had a poorer prognosis among all patients, patients with hepatocellular carcinoma (HCC), and those without HCC by log‐rank test. The multivariate Cox proportional hazards model identified female gender (hazard ratio [HR], 0.59; p = 0.03), alcoholic liver disease (HR, 4.25; p < 0.01), presence of HCC (HR, 6.77; p < 0.01), Child–Pugh classes A (HR, 1.42; p < 0.05), B (HR, 2.70; p < 0.01), and C (HR, 6.30; p < 0.01), and muscle weakness (HR, 2.24; p < 0.01) as significant adverse predictors. The cut‐off values of handgrip strength (HGS) for prognosis determined by maximally selected rank statistics were calculated as 27.8 kg for men and 18.8 kg for women. Conclusion Reduced HGS in patients with CLD was an independent adverse predictor of mortality, with cut‐off values of 27.8 kg for men and 18.8 kg for women.

show abstract

“…Sarcopenia, low muscle mass and low muscle strength result in a deteriorated clinical course of liver disease. [ 25 , 26 ] In addition, low muscle mass is associated with impaired HRQOL among patients with liver disease. Although we could not identify an association between ASMI and HRQOL, hand grip tended to be positively associated with the activity domain.…”

Section: Discussionmentioning

confidence: 99%

“…Effects of hand grip on QOL have been reported in digestive diseases, including liver disease in Japan. [ 26 ] The effects of skeletal mass or handgrip on HRQOL may thus be worth reanalyzing in a larger sample size.…”

Section: Discussionmentioning

confidence: 99%

Quality of life among patients with autoimmune hepatitis in remission

et al. 2020

View full text Add to dashboard Cite

Health-related quality of life (HRQOL) is lower in individuals with autoimmune hepatitis (AIH) than in the general population. However, previous evaluations of HRQOL for AIH have included a broad range of disease activities. The aim of this study was to clarify HRQOL among patients with AIH in remission. We assessed HRQOL in patients with AIH in remission, patients with chronic hepatitis C (CHC) with eradicated hepatitis C virus (HCV) and patients with primary biliary cholangitis (PBC) using the Japanese version of the Chronic Liver Disease Questionnaire (CLDQ). Participants comprised 62 patients with AIH in remission, 39 patients with CHC with eradicated HCV and 66 patients with PBC. Median ages of patients were 63, 69, and 64 years, respectively. Overall score (5.6 vs 5.9, P = .02) and fatigue (5.2 vs 5.6, P = .01) and worry (5.6 vs 6.0, P = .01) domain scores of the CLDQ were significantly lower in patients with AIH in remission than in CHC with eradicated HCV, and similar to scores except for the systemic symptoms domain in patients with PBC. Disease duration was associated with lower scores on systemic symptoms and activity domains of the CLDQ in patients with AIH in remission. Patients with AIH in remission show impaired HRQOL associated with disease duration.

show abstract

Relationship between pre-sarcopenia and quality of life in patients with chronic liver disease: a cross-sectional study

Cited by 18 publications

References 27 publications

Clinical utility of the Liver Frailty Index for predicting muscle atrophy in chronic liver disease patients with hepatocellular carcinoma

Clinical utility of the Liver Frailty Index for predicting muscle atrophy in chronic liver disease patients with hepatocellular carcinoma

Reduced handgrip strength predicts poorer survival in chronic liver diseases: A large multicenter study in Japan

Quality of life among patients with autoimmune hepatitis in remission

Contact Info

Product

Resources

About